

United Kingdom Facilities







3 commercial licenses

(E. coli and Pichia pastoris)



Robust and versatile CHO expression system, yields titers 5-7 g/L



Antibiotic

free E. coli expression system generating headline titers of up to 20 g/L



Billingham

~1,200 employees

Retention rate > UK average with microbial senior production technologists and above – average service >10 years

25 years Clinical & Commercial CDMO experience serving a plethora of unmet patient needs

≥£700M investments since 2022 across all modalities



- > 40 STEM ambassadors
- Winner of Northeast STEM awards
- Most inspirational employer
- 2023 and 2024
- Estimated social value > £1.5M



Award-winning multifunctional downstream purification

maru X

Europe's largest Single Use Facility — GMP continuous bioprocess available 2027



Medicines & Healthcare products Regulatory Agency

FUJIFILM Biotechnologies recently secured MHRA cGMP manufacturing licenses for products in our new viral and gene therapy facilities in Wilton and Darlington, UK



- **VGT Analytical** development / QC laboratories
- BSL-2 containment;
- Early Phase / First-inhuman up to 200 L

Mammalian Cell Culture, Microbial Fermentation

Process Development

CHO, E. coli, S. cerevisiae, P. pastoris Process and analytical development Cell Line Development, Molecular Biology, CDMO Innovation

Billingham - 70,000 sf Newton - 105,000 sf

MCC: Cytomine, AMBR 250, 2 L, 10 L,

Wave, 200 L, 500 L

Microbial: AMBR 250, 20 L, 100 L

Manufacturing

CHO cells, E. coli, S. cerevisiae, P. pastoris

- Cell Line Development
- Molecular biology
- CDMO innovation

 Process Development (including Drug Product)

cGMP Drug Substance Manufacturing

L, 2 x 2,000 L Microbial: 2 x 150 L, 2 x 4,000 L, 2 x 5,000 L

Single-Use Cell Culture: 1 x 500 L, 1 x 1,000

Expansions

Single-Use Cell Culture: 2 x 2,000 $L + 2 \times 5,000 L$ allowing multiple configuration option online from 2026 cGMP Continuous: on line 2027

Wilton

mAb Platform Process development Process Characterization, **Drug Product Process development** Cell based assay QC

Wilton - 40,000 sq ft

MCC: AMBR 250, AMBR 250 perfusion, 2 L, 10 L, 50 L, 200 L,500 L Microbial: AMBR 250, 2 L

Viral Gene Therapies

Process Development

Darlington

AAV, Adenovirus, Lentivirus Process and analytical development

Darlington ~2,000 sq ft

4 x 10 L, 50 L pilot Adherent up to 50 L

Manufacturing

Viral Gene Therapies - AAV, Adenovirus, Lentivirus

Single-Use Production:

1 x 50 L, 1 x 200 L

Clinical Phase I/IIa cGMP Manufacturing

Billingham

Process Development and pilot facility

Process and analytical development

Newton building - 15,000 sq ft

50 - 500 L SUBs

Cell and Gene Therapies. Viral Vectors, Oncolytic Viruses, Vaccines, Exosomes

cGMP manufacturing online 2027

50 -500 L SUBs

Partners for Life





fujifilmbiotechnologies.fujifilm.com



